Black Diamond Therapeutics (BDTX) Income from Continuing Operations (2018 - 2026)
Black Diamond Therapeutics (BDTX) posted Income from Continuing Operations of 11375000.0 for Q1 2026, up 35.24% on a QoQ basis from 17565000.0 in Q4 2025, and down 121.06% year-over-year from 54016000.0 in Q1 2025.
Black Diamond Therapeutics (BDTX) Income from Continuing Operations (2018 - 2026) Analysis & Trends
Black Diamond Therapeutics' Income from Continuing Operations history runs 9 years deep, the most recent figure standing at 11375000.0 for Q1 2026.
- Quarterly Income from Continuing Operations fell 121.06% year-over-year to 11375000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 57151000.0 (down 43.98% YoY) and the FY2025 annual result came in at 107640000.0, up 47.28% from the prior year.
- Income from Continuing Operations was 11375000.0 for Q1 2026 at Black Diamond Therapeutics, up from 17565000.0 in the prior quarter.
- Across five years, Income from Continuing Operations topped out at 54016000.0 in Q1 2025 and bottomed at 57265000.0 in Q3 2022.
- A 5-year average of 22501235.29 and a median of 21990000.0 in 2023 frame the typical range for Income from Continuing Operations.
- Annual changes were most pronounced in 2025 — Income from Continuing Operations soared 361.09% — and 2026, when it slumped 121.06%.
- Black Diamond Therapeutics' Income from Continuing Operations stood at 22226000.0 in 2022, then climbed by 2.77% to 21611000.0 in 2023, then gained by 12.92% to 18819000.0 in 2024, then gained by 6.66% to 17565000.0 in 2025, then soared by 35.24% to 11375000.0 in 2026.
- Business Quant data shows BDTX's Income from Continuing Operations at 11375000.0 in Q1 2026, 17565000.0 in Q4 2025, and 15325000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - | -37.09 Mn |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | -14.46 Mn |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn | 227.36 Mn |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn | 1.03 Bn |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn | 727.20 Mn |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - | -26.94 Mn |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn | 362.00 Mn |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - | -453.82 Mn |
| 10 | Black Diamond Therapeutics | 99.59 Mn | -18.67 Mn | - | -11.38 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -11.38 Mn |
| Dec 31, 2025 | -17.57 Mn |
| Sep 30, 2025 | -15.33 Mn |
| Jun 30, 2025 | -12.89 Mn |
| Mar 31, 2025 | 54.02 Mn |
| Dec 31, 2024 | -18.82 Mn |
| Sep 30, 2024 | -24.98 Mn |
| Jun 30, 2024 | -49.92 Mn |
| Mar 31, 2024 | -20.69 Mn |
| Dec 31, 2023 | -21.61 Mn |
| Sep 30, 2023 | -55.06 Mn |
| Jun 30, 2023 | -30.81 Mn |
| Mar 31, 2023 | -21.99 Mn |
| Dec 31, 2022 | -22.23 Mn |
| Sep 30, 2022 | -57.27 Mn |
| Jun 30, 2022 | -30.05 Mn |
| Mar 31, 2022 | -25.98 Mn |
| Dec 31, 2021 | -26.10 Mn |
| Sep 30, 2021 | -43.00 Mn |
| Jun 30, 2021 | -51.68 Mn |